Evidence map›Paper›PMID 41790114›Full record

ArticleCancer2026

The impact of the patient macroenvironment on molecular subgroups in endometrial cancer.

Henrica M J Werner, Frederiek A H van Dijk, Stephanie W Vrede, Anouk A S van den Bosch, Marike S Lombaers, Jasmin Asberger, Jutta Huvila, Marc Snijders, Valeria Tubita, Gemma Mancebo Moreno and 5 more

Abstract readMulticenter Study
In one paragraph

Article in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Henrica M J WernerDepartment of Obstetrics and Gynecology, Maastricht University Medical Center, Maastricht, the Netherlands.ORCID https://orcid.org/0000-0001-5186-8369
Frederiek A H van DijkFaculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.
Stephanie W VredeDepartment of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.
Anouk A S van den BoschDepartment of Obstetrics and Gynecology, Maastricht University Medical Center, Maastricht, the Netherlands.
Marike S LombaersDepartment of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0002-7384-2570
Jasmin AsbergerDepartment of Obstetrics and Gynaecology, Freiburg University Hospital, Freiburg, Germany.
Jutta HuvilaDepartment of Pathology, University of Turku, Turku, Finland.
Marc SnijdersDepartment of Gynaecology, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands.
Valeria TubitaBiomedical Research Group in Gynecology, Vall d'Hebron Institute of Research, Barcelona, Spain.
Gemma Mancebo MorenoDepartment of Obstetrics and Gynaecology, Hospital del Mar, Barcelona, Spain.
Xavier Matias-GuiuDepartment of Pathology and Molecular Genetics and Research Laboratory, CIBERONC, IRBLleida, University of Lleida, Hospital Universitari Arnau de Vilanova, Lleida, Spain.ORCID https://orcid.org/0000-0002-7201-6605
Petra BretováDepartment of Gynecology and Obstetrics, University Hospital Brno and Masaryk University, Brno, Czech Republic.
ENITEC Consortium
Vit WeinbergerDepartment of Gynecology and Obstetrics, University Hospital Brno and Masaryk University, Brno, Czech Republic.
Johanna M A PijnenborgDepartment of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than half of endometrial cancer diagnoses can be attributed to obesity. A purely molecular classification in endometrial cancer hampers further understanding of the impact of patient macroenvironment as a major risk factor. The relationship between patient factors, such as age, body mass index (BMI), comorbidity, and ethnicity, and molecular subgroups was studied in a publicly available data set (N = 225) and two multicenter European cohorts (N = 223; N = 946). Age at diagnosis was highest in the TP53-mutated subgroup, and differed significantly between molecular subgroups. Patients with obesity were younger at diagnosis compared to their lean counterparts across all molecular subgroups (61.9 vs. 66.2 years; p < .01). Survival was worst in the TP53-mutated subgroup but improved with increasing BMI, which resulted in nonsignificant differences from other subgroups when BMI was >35. These data underscore that patient factors remain important, and their integration with molecular factors needs to be better understood to ultimately improve treatment and prevention strategies in endometrial cancer.

Indexed as

Endometrial NeoplasmsObesityAgedAge FactorsBody Mass IndexComorbidityFemaleHumansMiddle AgedMutationPrognosisRisk FactorsTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53body mass indexcomorbidityendometrial neoplasm classificationethnicityhealth behaviorobesityprognosisrisk factors

Identifiers

PMID41790114
PMCPMC12965304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.